Fate Therapeutics Inc [FATE] stock prices are up 7.34% to $7.46 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The FATE shares have gain 5.67% over the last week, with a monthly amount glided 63.60%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates. In a post published today on Yahoo Finance, CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites.
From an analyst’s perspective:
Previously, H.C. Wainwright downgraded its rating to Neutral on January 24, 2023, and dropped its price target to $7. On January 06, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $7 on the stock. Truist downgraded its rating to a Hold and decreased its price target to $7 on January 06, 2023. Stifel downgraded its rating to a Hold and reduced its price target to $5.30 on January 06, 2023. Piper Sandler downgraded its rating to Neutral for this stock on January 06, 2023, and downed its price target to $12. In a note dated January 06, 2023, Cowen downgraded an Market Perform rating on this stock.
The stock price of Fate Therapeutics Inc [FATE] has been fluctuating between $1.63 and $7.74 over the past year. Currently, Wall Street analysts expect the stock to reach $51.67 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $7.46 at the most recent close of the market. An investor can expect a potential return of 592.63% based on the average FATE price forecast.
Analyzing the FATE fundamentals
The Fate Therapeutics Inc [NASDAQ:FATE] reported sales of 63.53M for trailing twelve months, representing a drop of -96.22%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.57 points at the first support level, and at 5.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.49, and for the 2nd resistance point, it is at 9.52.
Fate Therapeutics Inc [FATE] reported earnings per share of -$0.45 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.52/share, meaning a difference of $0.07 and a surprise factor of 13.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.46 per share as compared to estimates of -$0.57 per share, a difference of $0.11 representing a surprise of 19.30%.
Ratios To Look Out For
It’s worth pointing out that Fate Therapeutics Inc [NASDAQ:FATE]’s Current Ratio is 8.48. Further, the Quick Ratio stands at 8.48, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 11.58, the price to book ratio is 2.00.
Transactions by insiders
Recent insider trading involved Dulac Edward J III, Chief Financial Officer, that happened on Jan 29 when 1849.0 shares were sold. President and CEO, Wolchko J Scott completed a deal on Jan 09 to sell 14391.0 shares. Meanwhile, Chief R&D Officer Valamehr Bahram sold 11271.0 shares on Jan 09.
